MAIA Biotechnology, Inc. — Form 4
Filed September 1, 2026 · analyzed by the Insider Agent
4
▲ Likely positive
significance 52/100
What the filing says
Director Guerrero Ramiro (MAIA) bought 134K shares (~$184K) on the open market (15% of holdings). Open-market insider purchase — historically a bullish signal.
Why this rating
Open-market insider purchase — historically a bullish signal.
See more from September 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.